Cyprotex PLC Launch of New Enhanced Version of chemPK
May 17 2016 - 2:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
17 May 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Launch of New Enhanced Version of chemPK(TM) Workflow
Solution
for Predicting Human Pharmacokinetics Directly from Chemical
Structure
17(th) May 2016;
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the launch of version 2 of its
in silico modelling solution, chemPK(TM) , which predicts human
pharmacokinetics directly from chemical structure. Pharmacokinetics
is defined as the study of the concentration of a drug or chemical
in the body over time, and is related to its absorption,
distribution, metabolism and excretion. Understanding the
pharmacokinetics is important for understanding the efficacy
(effectiveness) or potential toxicity of drugs or chemicals
following their administration.
The original version of chemPK(TM) was able to predict human
pharmacokinetics following administration of a single oral dose.
Version 2 now has the ability to predict human pharmacokinetics
following administration of both oral and intravenous dose. It is
also able to simulate repeat-dose administration and so is more
relevant to the typical dosing regimen within the clinic. Unlike
most competing products, chemPK(TM) uses a PBPK
(physiologically-based pharmacokinetic) modelling approach which is
a more robust technique for this purpose. The software is easy to
implement and use. It operates on the freely available KNIME
Analytics Platform for workflow management which facilitates
integration with a wide range of other cheminformatics, analytics
and modelling tools.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
'chemPK(TM) is a valuable virtual screening tool which can be used
at an early stage prior to chemical synthesis of a molecule. The
recently developed version 2 improves the relevance of chemPK(TM)
to different dosing routes and regimens in the clinic. Cyprotex
have built an impressive range of software products for predicting
pharmacokinetic processes and toxicity which are now being utilised
within the industry for directing chemistry and prioritising in
vitro and in vivo screening.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1400 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, please visit www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKADDABKDNPD
(END) Dow Jones Newswires
May 17, 2016 02:01 ET (06:01 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024